摘要
目的评价我院晚期食管癌患者药物治疗方案中依从指南用药和未依从指南用药的有效性、安全性、经济性,为规范临床晚期食管癌患者诊疗提供依据。方法将135例住院晚期食管癌患者分为依从指南组(60例)和未依从指南组(75例),比较两组的抗肿瘤药物平均相对剂量强度;根据实体瘤疗效评价标准和常见不良事件评价标准比较抗肿瘤药物治疗方案的疗效及安全性;统计患者的住院费用、药品费用和抗肿瘤药物费用,比较抗肿瘤药物治疗方案的经济性。结果未依从指南组患者的平均相对剂量强度、客观缓解率、疾病控制率和药品不良反应发生率均高于依从指南组,但差异无统计学意义(P>0.05)。未依从指南组患者的住院费用、药品费用和抗肿瘤药物费用均显著高于依从指南组(P<0.001)。结论与未依从指南者比较,晚期食管癌患者药物治疗方案依从指南者的安全性和有效性可能无明显差异,但经济性较优。
Objective To evaluate the effectiveness,safety and economy of concordance and disconcordance guideline in the medication regimens of patients with advanced esophageal cancer in our hospital,and to provide a basis for standardizing the diagnosis and treatment of patients with advanced esophageal cancer.Methods 135hospitalized patients with advanced esophageal cancer were divided into concordance guideline group(60 cases)and disconcordance guideline group(75 cases),and the average relative dose intensity of antitumor drugs was compared between the two groups.The efficacy and safety of antitumor drug treatment were compared according to the response evaluation criteria in solid tumors and common terminology criteria adverse events.The hospitalization cost,drug cost and antitumor drug cost were analyzed to compare the economy of antitumor drug treatment.Results The average relative dose intensity,objective response rate,disease control rate and the incidence of adverse drug reaction in disconcordance guideline group were greater than those in concordance guideline group,but there were no statistically significant differences(P>0.05).The cost of hospitalization,medicine and anti-tumor drugs of disconcordance guideline group were greater than those of concordance guideline group(P<0.001)significantly.Conclusion There were no significant differences in the safety and effectiveness between the concordance and disconcordance guideline groups,but the economy of the concordance guideline group was better than that of disconcordance guideline group.
作者
汪楠
齐腊梅
黄灿
Nan WANG;La-Mei QI;Can HUANG(Department of Pharmacy Management,Anqing Municipal Hospital,Anqing 246000,Anhui Province,China)
出处
《药物流行病学杂志》
CAS
2023年第3期249-255,共7页
Chinese Journal of Pharmacoepidemiology
关键词
晚期食管癌
药物治疗
指南
有效性
安全性
经济性
Advanced esophageal cancer
Medical treatment
Guideline
Effectiveness
Safety
Economy
